Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors-Reference-Cited by-同舟云学术

Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors

Published:2019 Issue:1 Volume:15 Page:29
ISSN:2045-5275
Container-title:European Oncology & Haematology
language:en
Short-container-title:

Author:

Coleman Robert L,Ledermann Jonathan A, ,

Abstract

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Subject

Oncology,Hematology

Reference81 articles.

1. World Ovarian Cancer Coalition, The World Ovarian Cancer Coalition Atlas - Global Trends in incidence, mortality and survival, 2018. Available at: https://worldovariancancercoalition.org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf (accessed 20 June 2019).

2. US National Institutes of Health, SEER Cancer Statistics Review 1975-2014, 2015. Available at: https://seer.cancer.gov/archive/csr/1975_2014/results_merged/sect_21_ovary.pdf (accessed 17 December 2018).

3. American Cancer Society, Key statistics for ovarian cancer, 2019. Available at: www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html (accessed 7 March 2019).

4. National Institutes of Health, National Institutes of Health SEER Cancer Statistic Review 1975-2001-2015, 2018. Available at: https://seer.cancer.gov/archive/csr/1975_2001/results_merged/sect_20_ovary.pdf (accessed 17 December 2018).

5. Polyak K, Garber J. Targeting the missing links for cancer therapy. Nat Med. 2011;17:283–4.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib;Clinical Pharmacokinetics;2022-09-15